365 related articles for article (PubMed ID: 23636139)
1. Advances and challenges in the treatment of glioblastoma: a clinician's perspective.
Mrugala MM
Discov Med; 2013 Apr; 15(83):221-30. PubMed ID: 23636139
[TBL] [Abstract][Full Text] [Related]
2. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.
Gilbert MR
Semin Oncol; 2011 Dec; 38 Suppl 4():S21-33. PubMed ID: 22078645
[TBL] [Abstract][Full Text] [Related]
3. A novel treatment for glioblastoma: integrin inhibition.
Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in therapy for glioblastoma.
Clarke J; Butowski N; Chang S
Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
[TBL] [Abstract][Full Text] [Related]
5. Necroptosis: a novel therapeutic target for glioblastoma.
Jiang YG; Peng Y; Koussougbo KS
Med Hypotheses; 2011 Mar; 76(3):350-2. PubMed ID: 21075544
[TBL] [Abstract][Full Text] [Related]
6. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
7. Present and potential future issues in glioblastoma treatment.
Lefranc F; Sadeghi N; Camby I; Metens T; Dewitte O; Kiss R
Expert Rev Anticancer Ther; 2006 May; 6(5):719-32. PubMed ID: 16759163
[TBL] [Abstract][Full Text] [Related]
8. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
9. Molecular advances of brain tumors in radiation oncology.
Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
[TBL] [Abstract][Full Text] [Related]
10. Adult Glioblastoma.
Alexander BM; Cloughesy TF
J Clin Oncol; 2017 Jul; 35(21):2402-2409. PubMed ID: 28640706
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma multiforme: a review of where we have been and where we are going.
Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
[TBL] [Abstract][Full Text] [Related]
12. Management of Glioblastoma, Present and Future.
Oberheim Bush NA; Hervey-Jumper SL; Berger MS
World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma biomarkers from bench to bedside: advances and challenges.
Farias-Eisner G; Bank AM; Hwang BY; Appelboom G; Piazza MA; Bruce SS; Sander Connolly E
Br J Neurosurg; 2012 Apr; 26(2):189-94. PubMed ID: 22176646
[TBL] [Abstract][Full Text] [Related]
14. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma.
Cloughesy T
Semin Oncol; 2011 Dec; 38 Suppl 4():S11-20. PubMed ID: 22078643
[TBL] [Abstract][Full Text] [Related]
15. Glioblastoma multiforme: Pathogenesis and treatment.
Alifieris C; Trafalis DT
Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
[TBL] [Abstract][Full Text] [Related]
16. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
[TBL] [Abstract][Full Text] [Related]
17. Survival comparison between glioblastoma multiforme and other incurable cancers.
Tran B; Rosenthal MA
J Clin Neurosci; 2010 Apr; 17(4):417-21. PubMed ID: 20167494
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies for inhibiting invasion in glioblastoma.
Drappatz J; Norden AD; Wen PY
Expert Rev Neurother; 2009 Apr; 9(4):519-34. PubMed ID: 19344303
[TBL] [Abstract][Full Text] [Related]
19. [Glioblastoma in the elderly].
Laigle-Donadey F; Delattre JY
Geriatr Psychol Neuropsychiatr Vieil; 2011 Mar; 9(1):101-6. PubMed ID: 21586383
[TBL] [Abstract][Full Text] [Related]
20. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
